Short name: P792, generic name: Gadomeritol
A macromolecular Gd-DOTA derivate under development (phase II, Guerbet SA) as a positive enhancing blood pool agent (MRI contrast agent) for, e.g. myocard perfusion and tumor characterization.

See also Blood Pool Agents.

The France-based Guerbet Group is highly specialized in contrast media for medical imaging. Its strategic goal is to be a key player in this market. Products include Dotarem (Magnetic Resonance Imaging) and Xenetix (X-ray Imaging).

MRI Contrast Agents:

Short name: P792, generic name: Gadomeritol, preliminary trade name: Vistarem™, central moiety: Gd
A macromolecular Gd-DOTA derivate under development as a MRI blood pool agent with rapid clearance. Phase II of the clinical trials on P792 (Guerbet SA) will make it possible to validate the performance of this agent in the fields of angiography, myocardial perfusion and tumor characterization.